Chronic Obstructive Pulmonary Disease

Chronic obstructive pulmonary disease (COPD) is a progressive lung disease that lead to an irreversible loss of lung function. «Progressive» means the disease gets worse over time. COPD is characterized by hyperinflation of alveoli and destruction of alveolar architecture that causes decreased airway resistance.
TGV Therapeutics’ lead product is a nebulized Mul-1867 solution designed for convenient self-administration.  Mul-1867 (original nano-sized molecule 1.5-2.0 nm) the first inhaled antimicrobial being developed against multidrug-resistant bacteria and fungi and will be the breakthrough in war with lung infections in patients with COPD.

COPD hightlights
  • 4th leading cause of death in the US
  • By 2020 — 3rd leading cause of death in the US and worldwide
  • Characterized by chronically poor airflow
  • The main symptoms: shortness of breath, cough and sputum production
  • Bacterial and fungal infections cause 75% of the exacerbations

 

Mul-1867-CF provides treatment and protection for COPD patients that is:

  • More effective (no microorganisms are resistant to Mul-1867-CF)
  • Penetrate biofilms
  • Faster
  • Active against antibiotic-resistant strains across all bacteria and fungi in COPD patients